Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18055983 |
Eight mutation-positive cases were identified, including one with a previously undescribed mutant JAK2 exon 12 allele and another with biallelic involvement. |
| 18056003 |
JAK2 exon 12 mutations were detected in 4 out of 20 polycythemia vera and idiopathic erythrocytosis V617F-negative patients and were only present in the myeloid lineage |
| 18230964 |
observations suggest that the clinical phenotype of the JAK2 exon 12 mutation is partly different from that of the JAK2 V617F mutation |
| 18092959 |
Higher haemoglobin and lower platelet levels in the JAK2 V617F mutation positive essential thrombocythemia patients. |
| 18216871 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18239666 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18270328 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18294066 |
Observational study of genetic testing. (HuGE Navigator) |
| 18297539 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 18306358 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 18336541 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18343999 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18059484 |
HLA-G5 downregulates EPOR constitutive signaling of JAK2 V617F-expressing erythroleukemia cells, inhibiting cell proliferation via G1 cell cycle arrest. |
| 17984312 |
genetic predisposition to acquisition of different JAK2 mutations is inherited in families with myeloproliferative disorders |
| 17851561 |
JAK2V617F mutation precedes the development of MPD |
| 18223181 |
among the 101 myelodysplastic syndromes patients in our cohort, we detected JAK2 mutations |
| 18292125 |
4 of 11 patients with 'isolated erythrocythemia' were diagnosed as WHO-PV because of the presence of splenomegaly and 2 of them had JAK2 617V > F, suggesting the frequency of JAK2 617V > F mutation in PV depends on the diagnostic definition. |
| 16197451 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16247455 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16293597 |
Observational study of gene-disease association. (HuGE Navigator) |
| 16369984 |
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) |
| 16503548 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 16627272 |
Observational study of genetic testing. (HuGE Navigator) |
| 16762626 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17045648 |
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) |
| 17110452 |
Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) |
| 17263783 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17296594 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17307838 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17344140 |
Observational study of genotype prevalence and gene-disease association. (HuGE Navigator) |
| 17379742 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17408106 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17426257 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17439832 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17440677 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 17440984 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17460706 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17546465 |
Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) |
| 17577920 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17639043 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17712047 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17920754 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18006699 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18094555 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18166783 |
Observational study of gene-disease association. (HuGE Navigator) |
| 17625603 |
JAK2 V617F mutation is associated with polycythemia vera, essential thrombocythemia and primary myelofibrosis |
| 18165278 |
These data suggest that KIT(D816V+) systemic mastocytosis (SM) can co-exist with JAK2(V617F+) chronic idiopathic myelofibrosis (CIMF) and in some of these SM-CIMF cases, the two mutations are present in the neoplastic cells of both disease components. |
| 17851549 |
No JAK2 gene mutations or deletions are associated with Philadelphia chromosome-positive leukemia |
| 18081705 |
Parameters that are significantly associated with abnormal cytogenetics in polycythemia vera patients include age greater than or equal to 60 years, but not JAK2 Val617Phe allele burden. |
| 17949475 |
In a cohort study, prevalence of the JAK2 V617F mutation was low among unselected patients with a first episode of unprovoked venous thromboembolism.( |
| 18032883 |
JAK2(V617F)was identified in the bone marrow of 3 out of 237 B-cell lymphoma patients. It may arise in the bone marrow before clinical manifestation of any myeloid disorders & might increase the risk of future MPD development. |
| 17266061 |
A single point mutation (Val617Phe) was identified in JAK2 in 42 (73.7%) of 57 patients with polycythemia vera, 40 (58.8%) of 68 with essential thrombocythemia, and eight (66.7%) of 12 with myelofibrosis with myeloid metaplasia |
| 17712047 |
JAK2 V617F genotype should be considered in any future risk stratification of patients with primary myelofibrosis |
| 17707884 |
Using JAK2 V617F mutation as a molecular marker, we assessed paired spleen and bone marrow samples of 15 patients with various types of chronic myeloproliferative diseases and myeloproliferative/myelodysplastic diseases |
| 17577920 |
a correlation exists between the presence of V617F JAK2 mutation and selected hemostatic activation variables |
| 18035697 |
*n the mediastinal B-cell lymphoma cell line, harbouring trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated. |
| 17440677 |
The JAK2 V617F gene mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. |
| 17854308 |
more than 10% of the present 115 chronic myeloproliferative diseases patients had JAK2-V617F only in their platelets; detection of JAK2-V617F only in platelets was particularly frequent among essential thrombocythaemia patients |
| 18000612 |
intracellular mediators and pathways activated by leptin downstream of JAK2 were found to include phosphatidylinositol-3 kinase, phospholipase Cgamma2 and protein kinase C, as well as the p38 MAP kinase-phospholipase A(2) axis. |
| 17764814 |
ET Patients lacking the JAK2V617F mutation displayed significantly lower expression of the JAK/STAT target genes Pim-1 and suppressor of cytokine signaling-2. In addition, JAK2V617F-negative patients showed lower levels of STAT3 phosphorylation |
| 17764815 |
peripheral blood CD34+ cells from PV patients with high JAK2V617F burden contain NOD/SCID repopulating cells |
| 17920754 |
The JAK2V617F mutation was noted in a certain population of ET patients and correlated with leukocytosis, high hemoglobin level, and thrombosis |
| 17920755 |
there was significant disease spectrum overlap between JAK2 V617F and JAK2 exon 12 mutations. |
| 17976519 |
JAK2 attracts multiple gene partners and may contribute to disease progression in patients with MDS and B-cell malignancies, while the JAK2 copy number appears to be important in pathogenesis of Ph-negative MPDs. |
| 18003935 |
IL-27R possesses hematopoietic cell-transforming properties |
| 18045059 |
reviewsthe early history of Jak2 as it pertains to its role in classical cellular signaling, how specific structural determinants within Jak2 dictate its overall function, and the role of Jak2 in neoplastic growth [review] |
| 17727557 |
current evidence suggests that JAK2 V617F mutation has significant impact on signal pathways in myeloproliferative disorders [review] |
| 17761748 |
the JAK2 V617F mutation was detected in 26 samples derived from bone marrow or blood and in 24 of 26 (92.3%) samples derived from matching buccal swabs of patients with Philadelphia-negative chronic myeloproliferative disorders |
| 17625610 |
The finding of non-germline JAK2V617F mutations in a family with polycythemia vera shows that the mutation is a secondary event to still-unknown primary genetic aberrations causing an inherited tendency for hematopoietic cells to acquire the mutation. |
| 17611555 |
No aberrant size bands were found using cDNA-specific primers to exons 13 & 15 in 15 homozygous V617F-positive myeloproliferative disease cases. Amplification of the mutant JAK2 is not a common factor in the evolution of JAK2 V617F-positive disease. |
| 17611562 |
Unlike the risk of thrombosis in essential thrombocythemia, the risk in polycythemia vera is not linked to JAK2V617F mutational status. |
| 17982107 |
Jak2 ordinarily dampens and limits the duration of the PGHS-2 induction by IL-1beta. |
| 17262192 |
Megakaryocytes might be the predominant or even the exclusive lineage that acquires the JAK2(V617F) mutation in essential thrombocythemia. |
| 17983808 |
A novel signaling pathway, in which NADPH oxidase activation results in inhibition of protein tyrosine phosphatases, leading to enhanced and sustained phosphorylation of kinases (JAK2), and suppression of apoptosis is suggested in pancreatic neoplasms. |
| 17452518 |
JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year |
| 16912864 |
Leptin stimulates proliferation and inhibits apoptosis in colon cancer cells. This effect involves JAK2, PI3 kinase and JNK and activation of the oncogenic transcription factors signal transducer and activator of transcription |
| 17581610 |
JAK2-V617F activating mutation may have a role in acute myeloid leukemia |
| 17652621 |
In lymphocyte-predominant Hodgkin lymphoma SOCS1 function may thus be frequently impaired by mutations, and this may contribute to high JAK2 expression and activation of the JAK2/STAT6 pathway. |
| 17703302 |
Six out of 18 patients with slightly elevated platelets or hemoglobin were positive for the JAK2 mutation, five of these six had a history of thrombosis |
| 17961178 |
the JAK2 V617F allele may have a role in essential thrombocythemia, polycythemia vera and primary myelofibrosis |
| 17726017 |
The role of the JAK2 pathway in the regulation of IL8 transcription by Ox-PAPC in vitro and in atherosclerosis in vivo is reported. |
| 17540852 |
Clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations. |
| 17573918 |
platelet CD36 increase may be independent from the JAK2 V617F mutation in essential thrombocytopenia |
| 17639043 |
Haplotypes in the JAK2 gene were not associated with the risk of breast cancer. |
| 17875526 |
The JAK2 V617F mutation is prevalent in all Philadelphia chromosome-negative MPD and may skew their presenting phenotype, including bone marrow histology, toward a more "erythremic" and less "thrombocythemic" phenotype. |
| 16617322 |
JAK2 V617F mutation was detected in a cohort of patients with 5q- syndrome and a hypercellular marrow |
| 17389763 |
results suggest for polycythemia vera, erythrocytosis can occur through 2 mechanisms: terminal erythroid amplification triggered by JAK2 617V>F homozygosity & a 2-step process including the upstream amplification of heterozygous cells |
| 17849060 |
Describe patient with fatal Budd-Chiari syndrome in whom JAK2 and factor V Leiden mutations were found. |
| 17392820 |
data indicate that JAK2(V617F)-positive essential thrombocythemia can develop thrombosis at any time |
| 17881638 |
report a new mutation in the JAK2 gene locus |
| 17989398 |
The JAK2 V617F mutation, which occurs in 0.20% of normal primigravidas between the ages of 21 and 36 years who live in the Mediterranean region of southern Europe, is associated with an increased risk of pregnancy loss. |
| 17379742 |
study concludes that JAK2 617V>F homozygosity identifies polycythemia vera or essential thrombocythemia(ET) patients with a more symptomatic myeloproliferative disorder & is associated with a higher risk of major cardiovascular events in patients with ET |
| 17643100 |
JAK2 V617F mutation is frequently present in splenic extramedullary hematopoietic (EMH) cells associated with chronic myeloproliferative disorders, but it is rarely identified in EMH cells associated with other myeloid disorders. |
| 17507997 |
JAK2 V617F neutrophil allele does not have a role in thrombotic risk in essential thrombocytosis |
| 17507998 |
MPLW515K, but not JAK2V617F, is expressed in in vitro expanded CD4+ T lymphocytes from primary myelofibrosis patients |
| 17625612 |
AML1-ETO and JAK2 may have a role in leukemogenesis, as shown by a myeloproliferative syndrome progressing to acute myeloid leukemia [case report] |
| 16563504 |
Amongst 42 consecutive patients with leukemic transformation (LT) from myelofibrosis with myeloid metaplasia (MMM) 72% carried the JAK2(V617F) mutation. The mutation was observed at expected frequencies in all subtypes of MMM and acute myeloid leukemia. |
| 17597810 |
6 of a total 220 cases with polycythemia vera that were JAK2V617F-negative (prevalence=3%); five cases were found to harbor one of the two JAK2 exon 12 mutations (F537-K539delinsL or N542-E543del) in bone marrow and/or peripheral blood cells |
| 17625606 |
that a burden of JAK2(V617F) allele greater than 75% at diagnosis points to polycythemia vera patients with high-risk disease |
| 17476276 |
results are underwhelming for clinical relavence of JAK2V617F alleles burden in polycythemia vera |
| 16886215 |
The JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders |
| 17151700 |
V617F mutation is observed also in acute and chronic myeloid malignancies (acute myeloid leukemia and chronic myelomonocytic leukemia |
| 17476275 |
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors is associated with myelofibrosis |
| 17488346 |
JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder |
| 17596137 |
JAK2 V6I7 F mutation may have a role in thrombosis in myeloproliferative diseases |
| 17689208 |
Sodium arsenite dose dependently alters STAT3 and JAK2 activities via Bcl-6 and this may have a role in arsenic-associated carcinogenesis. |
| 17408106 |
data add to the observation that the JAK2 V617F mutation seems to be rather uncommon in myeloid malignancies other than the classic BCR/ABL negative MPD |
| 16537803 |
study of 72 families with myeloproliferative disorder does not support existence of germ-line Val617Phe JAK2 mutation as a predisposing factor; homozygous JAK2 mutation confers a proliferative advantage & is associated with disease progression |
| 17363731 |
JAK2-V617F-positive MPD frequently yields JAK2-V617F-negative AML, and transformation of a common JAK2-V617F-negative ancestor represents a possible mechanism. |
| 17443220 |
JAK2 mutation is associated with Acute Myelocytic Leukemia and Myeloproliferative Disorders |
| 17169814 |
the JAK2 V617F mutation is absent in chronic lymphocytic leukemia |
| 17376889 |
In all evaluated MPDs, the pSTAT-5 and pSTAT-3 expression pattern was not influenced by the presence of V617F JAK2 mutation |
| 17460706 |
JAK2V617F mutation is associated with non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder |
| 17625156 |
it was postulated that JAK2 V617F mutation may play a role in pancreatic cancer; no such mutations were detected at the JAK2 617 codon for pancreatic cancer or cell samples |
| 17426257 |
Patients carrying the JAK2 (617V>F) mutation have higher risk of developing pregnancy complications and abortion. |
| 17111143 |
molecular detection of JAK2 mutation heralded extramedullary relapse in our case |
| 17613428 |
JAK2-V617F mutation is associated with Philadelphia-chromosome-positive chronic myeloid leukaemia |
| 15863514 |
a gain-of-function mutation of JAK may explain the hypersensitivity of polycythemia vera progenitor cells to growth factors and cytokines |
| 16079889 |
JAK2 Val617Phe activating tyrosine kinase mutation is associated with juvenile myelomonocytic leukemia |
| 15985214 |
mutated in polycythemia vera |
| 16084028 |
mutated in myeloproliferative disorders and hematologic cancers. (review) |
| 16929538 |
A 52-year-old man developed essential thrombocythemia with JAK2 V617F mutation after orthotopic liver transplantation. |
| 16930139 |
Fli-1 is rather constitutively expressed by bone marrow cells in Ph(-) CMPD independent of the underlying JAK2 status |
| 12106016 |
The mechanisms by which HNF-4 is modified after injury involve the activation of Janus kinase 2 (JAK2) signal transduction pathways, but the direct or indirect interaction of JAK2 with HNF-4 remains to be defined. |
| 16280321 |
JAK1/2 are client proteins of Hsp90 alpha and beta; Hsp90 and CDC37 play a critical role in types I and II interferon pathways |
| 16434490 |
JAK2V617F mutation may be sufficient for the development of polycythemia vera, but additional genetic events are necessary in essential thrombocythemia and myeloid metaplasia/myelofibrosis. |
| 17267906 |
JAK2 exon 12 mutations define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis. |
| 16557239 |
This study suggested that JAK2 mutation is a sole but specific mutation in acute leukemia from MPDs. |
| 16959222 |
Curcumin treatment inhibited Jak2 mRNA expression in K562 chronic leukaemia cells. |
| 17389152 |
role of JAK2 V617F mutation in chronic myeloproliferative disorders (Review) |
| 16204151 |
V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders |
| 16923108 |
frequency of the JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status |
| 16926301 |
Found in a subset of patients with JAK2-V617F mutation and essential thrombocythemia. |
| 17296594 |
a V617F mutation of JAK2 is very uncommon in patients with thrombosis |
| 12370803 |
Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. |
| 16572198 |
Direct sequencing confirmed the specificity of the assay, which has a detection limit congruent with1% and allowed to identify 9% more JAK2-mutated patients as compared to conventional allele-specific PCR. |
| 16598306 |
Janus kinase2 extrinsic regulators and other proteins in the JAK-STAT pathway should be interrogated to explain frequent STAT activation in AML. |
| 16598312 |
The JAK2 mutation can be acquired during disease progression of myelodysplastic syndrome JMML. |
| 16987804 |
observation contributes to the overall clinical specificity of the JAK2 V617F mutation |
| 17249502 |
The JAK2 mutation may help differentiate nMPD from secondary cytosis. |
| 15985544 |
Presence of the Jak2V617F mutation was very highly correlated with polycythemia rubra vera 1 overexpression |
| 16420986 |
A mutation in exon 12 of the JAK2 tyrosine kinase gene, leading to a substitution of a valine to a phenylalanine has been described in most polycythaemia patients. (review) |
| 16877349 |
The expression of matrix-modeling genes in chronic idiopathic myelofibrosis (cIMF) is not influenced by the JAK2 mutation status but is predominantly related to the stage of disease. |
| 17052978 |
study suggests that whereas cell surface expression of type I cytokine receptors requires their cognate JAKs, the mechanisms governing receptor-JAK interactions differ among receptors interacting with the same JAK protein |
| 17237409 |
using choriocarcinoma cells, it is shown that tyrosine phosphatase mediated suppression of IFN-gamma-inducible JAK and STAT-1 and select IFN-gamma-inducible gene expression in trophoblast cells may contribute to fetal maintenance |
| 12777975 |
Data suggest there is no defect in the JAK/STAT pathway in the tested melanoma cell lines, and that interferon resistance must be mediated through other components. |
| 15611059 |
CXCL12 signaling is independent of Jak2 and Jak3 |
| 15677497 |
In human nonfailing myocytes, high glucose allows Angiotensin II to activate JAK2 signaling. |
| 16831057 |
This assay identifies JAK2(V617F) in a clinical laboratory setting. The detection of JAK2(V617F) in archived specimens is a new tool for studying the prognostic significance of the mutation of this gene. |
| 15688010 |
Similar to SOCS-1, Tkip peptide binds to the autophosphorylation site of JAK2. |
| 15837627 |
A somatic mutation JAK2V617F was found in granulocyte DNA from 121 of 164 polycythemia vera patients, from 37 of 115 essential thrombocythemia patients, and from 16 of 46 myeloid metaplasia with myelofibrosis patients. |
| 16174768 |
crystal structure of the active conformation of the JAK2 PTK domain in complex with a high-affinity, pan-JAK inhibitor that appears to bind via an induced fit mechanism |
| 12223098 |
requirement in interferon-gamma-mediated inhibition in human chondrocytes |
| 15198092 |
Although the methylation frequency of SOCS-1 is low, the data of Fujitake et al. indicate role of JAK/STAT/SOCS pathway in gastrointestinal tumorigenesis. |
| 12478664 |
JAK2 has an important pathologic role in Hodgkin's lymphoma |
| 15358195 |
Protein tyrosine phosphatase 1-B levels increased with introduction of wt p53 and may be involved in the dephosphorylation of JAK2 |
| 16502590 |
single acquired amino acid substistution in the JAK2 gene has recently been described in human myeloproliferative disorders. |
| 16572200 |
the results suggested that JAK2 V617F is unlikely to play a significant role in the pathobiology of MDS, with or without secondary myelofibrosis. |
| 16603627 |
The JAK2 V617F mutation was detectable within hematopoietic stem cells and their progeny in polycythemia vera. |
| 16620973 |
JAK2V617F mutation is absent in idiopathic erythrocytosis and may represent a useful molecular marker for distinguishing it from polycythemia vera. |
| 16741247 |
RARS-T has a high frequency of the JAK2 V617F mutation |
| 16847321 |
Data demonstrate that nuclear Jak2 regulates the amount of active NF1-C2 through tyrosine phosphorylation and proteasomal degradation. |
| 16873677 |
patients with and without the JAK2 mutation have different patterns of cytogenetic abnormality, with virtually all patients carrying the 20q deletion or trisomy 9 being V617F(+). |
| 17440984 |
Mutations in JAK2 is associated with essential thrombocythemia |
| 11940567 |
Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells |
| 12552091 |
JAK2 phosphorylation is suppressed by estrogen, which inhibits growth hormone signaling |
| 15781101 |
A single acquired mutation of JAK2 was noted in more than half of patients with a myeloproliferative disorder. |
| 15988755 |
JAK1 and JAK2 must work cooperatively and not independently and that their actions are dependent on having normal kinase activity to trigger downstream signals leading to Interleukin-3 independent proliferation |
| 16247455 |
This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs |
| 16257269 |
the activation of JAK2 plays a pivotal role in oxidant stress-induced commitment of endothelial cells to apoptosis |
| 16257270 |
Jak2 has a protective role in maintaining inositol 1,4,5 trisphosphate receptor expression |
| 16849644 |
evaluated the clonality status and V617FJAK2 mutation in 20 children affected by ET and compared them with 47 consecutive adult ET cases |
| 16871275 |
mutant JAK2 contributes to myelofibrosis with myeloid metaplasia pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis |
| 16885051 |
JAK2Val617Phe-negative case of essential thrombocythemia harboring the acquired translocation t(X;5)(q13;q33). |
| 17045648 |
JAK2 point mutation is associated with myeloproliferative disorders |
| 17110452 |
presence of JAK2 V617F was not identified as a risk factor for thrombosis during follow-up despite a significant association between the mutation and leukocytosis |
| 17229651 |
JAK2 V617F mutation status has a role in risk of thrombosis in patients with essential thrombocythemia and polycythemia vera |
| 17229652 |
JAK2 V617F mutations in CBF leukemias have a role in disease progression |
| 17263783 |
the JAK2 V617F mutation may have a role in splanchnic or cerebral venous thrombosis in patients without overt chronic myeloproliferative disorders |
| 14551204 |
Jak2 is required for Ang II-induced ERK2 inactivation via induction of MKP-1 gene expression. |
| 14522994 |
Janus kinase 2 ubiquitination/degradation downstream of the prolactin receptor is regulated by SHP-2 and mediated by SOCS-1 |
| 16091753 |
A genetic translocation in atypical chronic myeloid leukemia yields a new PCM1-JAK2 fusion gene. |
| 11923474 |
increase in cyclin d-1 promoter activity is predominantly mediated by the Jak2/Stat5 signaling pathway |
| 12351625 |
the JH2 domain contributes to both the uninduced and ligand-induced Jak-receptor complex, where it acts as a cytokine-inducible switch to regulate signal transduction |
| 15927298 |
Leptin enhances ADP-induced caalcium increases via JAK2 and tyrosine kinases in a megakaryoblast cell line. |
| 16084495 |
CaM binds to the membrane-proximal EpoR cytoplasmic region and plays an essential role in activation of Jak2-mediated EpoR signaling |
| 16497804 |
susceptibility of GHR to proteolysis is substantially affected by JAK2, suggesting yet another role for this kinase in determining GH sensitivity. |
| 16728702 |
allelic frequency of the JAK2-V617F mutation in DNA and expression levels of the mutant and wild-type JAK2 mRNA in granulocytes from 60 patients with essential thrombocythemia and 62 patients with polycythemia vera at the time of diagnosis |
| 16757685 |
Although the JAK2(V617F) mutation plays an important role in the biologic origins of polycythemia vera, it is likely not the sole event leading to this disease. |
| 16772604 |
the V617F mutation of JAK2 may have a role in polycythemia vera, but not in essential thrombocythemia |
| 16982687 |
Collectively, the results suggest that Jak2 is the sole direct signaling molecule downstream of EpoR required for biological activity. |
| 17198871 |
data supports a model wherein the JAK2(V617F) mutation arises as a secondary genetic event; results indicate that an undefined molecular lesion, preceding JAK2(V617F), is responsible for clonal hematopoiesis in PV |
| 17439832 |
V617F mutations were detected in 17% (7 patients) with catastrophic intra-abdominal thromboses resulting in visceral transplants |
| 17509995 |
Detection of the monomorphic JAK2 V617F mutation using the ACB-PCR assay is easy to perform, rapid, sensitive, and cost-effective. |
| 15666812 |
Jak2 is novel pathway in Ang II-dependent activation of StAR expression and steroidogenesis in adrenocortical cells and is requirement for ongoing protein synthesis in Ang II-mediated StAR transcription. |
| 16442619 |
Previously described increase of expression and kinase activity of JAK2 in chronic myelocytic leukemia cells does not result from JAK2 activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation. |
| 16828865 |
Atiprimod decreased phosphorylation of Stat3 and Stat5, and protein levels of Jak2, whereas gene expression of Jak2 was not affected in myeloid leukemia cells. |
| 16954506 |
The JAK2 V617F mutation in PV and IMF drives a lymphomyeloid stem cell. The phenotype derives from the proliferative advantage this gives to the myeloid series. |
| 17012261 |
The Ras/Raf-1/MEK1/ERK cascade culminates in nicotine up-regulated expression of the gene encoding STAT-3, whereas recruitment and activation of tyrosine kinase JAK-2 phosphorylates it. |
| 17057021 |
Splanchnic vein thrombosis caused by myeloproliferative disorders as revealed by JAK2 mutation. |
| 17190855 |
The JAK2V61F allele in a polycythemia vera patient was found in hematopoietic stem cells and common myeloid progenitors but not mature lymphoid cells. |
| 17296581 |
JAK2V617F-positive patients with idiopathic myelofibrosis show involvement of B-, T-, and NK-cell lineage |
| 15676212 |
tel-jak2a fusion oncoprotein based on that seen in a case of chronic myeloid leukemia in zebrafish caused revealed disruption of normal embryonic hematopoiesis, including perturbation of the myeloid and erythroid lineages. |
| 14565954 |
Janus kinase 2 and calcium are required for angiotensin II-dependent activation of steroidogenic acute regulatory protein transcription |
| 15604419 |
Jak2 activation is sufficient for GTPCH I upregulation in response to IFN-gamma and its synergy with TNF-alpha. |
| 15793561 |
a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients |
| 16034466 |
The rearrangement created by the t(8;9)(p22;p24)used dual-colour FISH on metaphases from patient cells using labelled-BAC clones centred on JAK2. |
| 12456871 |
theoretical model of Janus kinase 2 comprising all seven Janus homology domains |
| 15615703 |
The N-terminal part of the 1st intracellular loop (ICL) is needed to activate Jak2 after SDF-1alpha binding to CXCR4, leading to phosphorylation of only one cytoplasmic Tyr, present at the C terminus of the 2nd (ICL), which triggers STAT3 activation. |
| 15860661 |
current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders |
| 15858187 |
A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2. |
| 16365288 |
JAK2V617F has a role in diseases of myeloid lineage cells that express these Type I cytokine receptors but not in lymphoid lineage cells that do not |
| 16804112 |
identified a new JAK2T875N mutation in the AMKL cell line CHRF-288-11 |
| 16868251 |
MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease |
| 16904848 |
Review. Current hypotheses on how JAK2 V617F contributes to three myeloproliferative diseases are discussed. |
| 16959246 |
This is the first reported case of chronic idiopathic myelofibrosis associated with a reciprocal 3;9 translocation with the 3q21 and 9p24 breakpoints. |
| 17344916 |
we detected expression of JAK2 V617F in MDS-AML but not in RA or RAEB, suggesting that expression of JAK2 V617F may be one of the genetic factors involved in the progression of MDS to AML with a megakaryoblastic nature |
| 15923602 |
Data show that medroxyprogesterone acetate treatment of mammary tumor cells up-regulated Stat3 protein expression and induced rapid, nongenomic Stat3, Jak1, and Jak2 tyrosine phosphorylation. |
| 16373657 |
A JAK2 (V617F) gene dosage effect on both CD34(+) cell counts and granulocyte activation was clearly demonstrated in polycythemia vera, where abnormal patterns were mainly found in patients carrying more than 50% mutant alleles. |
| 16632470 |
regulation of cyclin D2 and p27(Kip) in combination with redox-dependent processes promotes G(1)/S phase transition downstream of Jak2V617F/STAT5 |
| 16888614 |
presence of JAK2 V617F in all myeloid cells in essential thrombocythemia |
| 16932338 |
JAK2 V617F mutation provides a prolierative signal to the dysplastic clone, which manifests itself by megakaryocytopoiesis in myelodysplastic diseases |
| 16990759 |
JAK2 V617F mutation is common in refractory sideroblastic anemia with thrombocytosis |
| 16990780 |
it is likely that JAK2V617F mutation may be present in virtually all polycythemia vera patients |
| 17077140 |
expression of TEL-JAK2, a constitutively active variant of the JAK2 kinase, in lineage-depleted umbilical cord blood cells results in erythropoietin-independent erythroid differentiation in vitro and induces the rapid development of myelofibrosis |
| 17054914 |
These findings suggest that the activation of JAK2, but not STAT3, may play a critical role in leptin-induced AMPK activation in Huh7 cells. |
| 17068151 |
JAK-STAT pathway may contribute to lymphoid malignancies and hematologic disorders observed in children with Down syndrome |
| 17105449 |
a mutation of Janus kinase 2 is not responsible for B cell chronic lymphocytic leukemia developing in a patient with Polycythemia Vera |
| 17315023 |
results may suggest that the mutational status of JAK2(V617F) is associated with clinical features that represent disease progression of various chronic myeloproliferative disorder subtypes |
| 17403204 |
JAK2 V617F may have a role in idiopathic splanchnic vein thrombosis |
